Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000202472 | SCV001214137 | pathogenic | Carnitine palmitoyltransferase II deficiency | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 631 of the CPT2 protein (p.Arg631Cys). This variant is present in population databases (rs74315293, gnomAD 0.01%). This missense change has been observed in individual(s) with CPTII deficiency (PMID: 1528846, 15754283, 16996287, 17651973; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 8952). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CPT2 protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV001781211 | SCV002019726 | pathogenic | not provided | 2021-02-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001781211 | SCV002513152 | pathogenic | not provided | 2022-04-26 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect (significant reduction of enzyme activity compared to wildtype) (Taroni et al., 1992); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 9600456, 17651973, 22975760, 1528846, 8358442, 20810031, 21913903, 15754283) |
Fulgent Genetics, |
RCV002476950 | SCV002791054 | pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form; Carnitine palmitoyl transferase II deficiency, myopathic form; Carnitine palmitoyl transferase II deficiency, neonatal form; Encephalopathy, acute, infection-induced, susceptibility to, 4 | 2021-08-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000009508 | SCV004178345 | pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003473062 | SCV004211049 | pathogenic | Encephalopathy, acute, infection-induced, susceptibility to, 4 | 2024-03-11 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000009508 | SCV000029726 | pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form | 1993-07-01 | no assertion criteria provided | literature only | |
Gene |
RCV000202472 | SCV000153673 | not provided | Carnitine palmitoyltransferase II deficiency | no assertion provided | literature only | ||
OMIM | RCV000415574 | SCV000493924 | pathogenic | Carnitine palmitoyl transferase II deficiency, myopathic form | 1993-07-01 | no assertion criteria provided | literature only | |
Natera, |
RCV000202472 | SCV001454248 | pathogenic | Carnitine palmitoyltransferase II deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |